Sanofi: price target raised at Barclays

(CercleFinance.com) - Barclays reaffirms its 'overweight' recommendation on Sanofi, with a price target raised from €120 to €125, believing that 2025 could be the year that sees the French healthcare giant's shares break through the €105 barrier.


'Although Dupixent missed expectations in the quarter, everything else at Sanofi is progressing well (and we believe that the launch in COPD this year should benefit Dupixent)', says the broker in the summary of its note.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.